Inovio Pharmaceuticals Under Investigation for Possible Securities Law Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy INO?
Source: Businesswire
- Financial Reporting Delay: Inovio's Q2 2024 financial results, released on August 8, revealed a delay in submitting the Biologics License Application for INO-3107 to mid-2025 due to manufacturing issues, undermining investor confidence and expectations.
- Stock Price Impact: Following this announcement, Inovio's stock price fell by $0.27, or 3.1%, to close at $8.44 per share on August 9, resulting in significant losses for investors.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA under a standard review timeline instead of the accelerated timeline previously promoted, further eroding market confidence and investor sentiment.
- Significant Stock Volatility: This news led to a dramatic drop in Inovio's stock price by $0.56, or 24.45%, closing at $1.73 per share on December 29, compounding the financial losses for investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.610
Low
3.00
Averages
7.33
High
13.00
Current: 1.610
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Under Investigation for Possible Securities Law Violations
- Financial Reporting Delay: Inovio's Q2 2024 financial results, released on August 8, revealed a delay in submitting the Biologics License Application for INO-3107 to mid-2025 due to manufacturing issues, undermining investor confidence and expectations.
- Stock Price Impact: Following this announcement, Inovio's stock price fell by $0.27, or 3.1%, to close at $8.44 per share on August 9, resulting in significant losses for investors.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA under a standard review timeline instead of the accelerated timeline previously promoted, further eroding market confidence and investor sentiment.
- Significant Stock Volatility: This news led to a dramatic drop in Inovio's stock price by $0.56, or 24.45%, closing at $1.73 per share on December 29, compounding the financial losses for investors.
See More
Inovio Pharmaceuticals Under Investigation, Stock Price Plummets
- Legal Investigation Launched: The Law Offices of Howard G. Smith announced an investigation into Inovio Pharmaceuticals regarding potential violations of federal securities laws, indicating that investors may face further losses.
- Earnings Report Impact: On August 8, 2024, Inovio released its Q2 financial results, revealing a delay in submitting the Biologics License Application to mid-2025 due to manufacturing issues, causing its stock to drop 3.1% to $8.44 per share the following day, directly impacting investor confidence.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 application but did not receive accelerated review, leading to a 24.45% stock price drop to $1.73 per share, further exacerbating investor losses.
- Investor Rights Affected: Due to the company's failure to meet submission timelines and changes in review status, investors are facing significant financial losses, prompting the Law Offices of Howard G. Smith to urge affected investors to reach out for potential claims to recover losses.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Inovio Pharmaceuticals on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 7, 2026, indicating the urgency of legal recourse.
- False Statements Allegations: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which misled investors regarding the prospects of the INO-3107 Biologics License Application, thereby undermining investor confidence.
- FDA Review Developments: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, highlighting significant regulatory compliance challenges for Inovio.
- Stock Price Volatility: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73, reflecting market pessimism regarding the company's prospects and investor concerns over potential losses.
See More
INOVIO to Participate in Multiple Scientific and Investor Conferences
- Conference Participation: INOVIO will present its DNA immunotherapy INO-3107 at the American Association for Cancer Research Immuno-Oncology Conference on February 18 in Los Angeles, showcasing its ability to activate and enrich CD4+ T cell responses in clinical patients, which is expected to enhance the company's visibility in cancer treatment.
- Virtual Conference Engagement: The company will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, sharing the latest advancements in DNA drug development, thereby attracting investor interest and bolstering market confidence.
- Biologics Festival Presentation: On March 4, INOVIO will present the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies at the Festival of Biologics in San Diego, demonstrating its research achievements in combating COVID-19, which could enhance the company's influence in the biopharmaceutical sector.
- Investor Meeting Schedule: During the Citizens Life Sciences Conference on March 10, INOVIO will conduct one-on-one meetings with investors, aiming to strengthen investor trust through direct engagement and facilitate future capital inflows.
See More
Inovio Pharmaceuticals Faces Class Action for Securities Fraud
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the period from October 10, 2023, to December 26, 2025, with a deadline of April 7, 2026.
- False Statement Allegations: The complaint alleges that Inovio made false and misleading statements to the market, indicating that manufacturing deficiencies with its CELLECTRA device were likely to delay its BLA filing with the FDA.
- Evidence Collection Issues: The company failed to gather the necessary evidence to support a priority review by the FDA, meaning its public statements were false and materially misleading throughout the class period, potentially leading to investor losses.
- Investor Participation Opportunity: DJS Law Group encourages shareholders who purchased Inovio stock during the class period to contact them to participate in the lawsuit, noting that appointment as lead plaintiff is not required to partake in any recovery, emphasizing their commitment to investor rights.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Inovio Pharmaceuticals on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, to apply as lead plaintiff.
- Allegation Details: The lawsuit claims that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which affected the likelihood of submitting the INO-3107 Biologics License Application (BLA) on time, thereby overstating its regulatory and commercial prospects.
- Stock Price Reaction: Following the FDA's acceptance of INO-3107's BLA application, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting market pessimism regarding the company's future.
- Next Steps: Investors who suffered losses during the class period or have questions about the allegations are encouraged to contact Bragar Eagel & Squire for more information and to explore their legal rights, indicating the firm's commitment to investor advocacy.
See More
Inovio Pharmaceuticals Under Investigation for Possible Securities Law Violations
- Financial Reporting Delay: Inovio's Q2 2024 financial results, released on August 8, revealed a delay in submitting the Biologics License Application for INO-3107 to mid-2025 due to manufacturing issues, undermining investor confidence and expectations.
- Stock Price Impact: Following this announcement, Inovio's stock price fell by $0.27, or 3.1%, to close at $8.44 per share on August 9, resulting in significant losses for investors.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted the INO-3107 BLA under a standard review timeline instead of the accelerated timeline previously promoted, further eroding market confidence and investor sentiment.
- Significant Stock Volatility: This news led to a dramatic drop in Inovio's stock price by $0.56, or 24.45%, closing at $1.73 per share on December 29, compounding the financial losses for investors.
See More
Inovio Pharmaceuticals Under Investigation, Stock Price Plummets
- Legal Investigation Launched: The Law Offices of Howard G. Smith announced an investigation into Inovio Pharmaceuticals regarding potential violations of federal securities laws, indicating that investors may face further losses.
- Earnings Report Impact: On August 8, 2024, Inovio released its Q2 financial results, revealing a delay in submitting the Biologics License Application to mid-2025 due to manufacturing issues, causing its stock to drop 3.1% to $8.44 per share the following day, directly impacting investor confidence.
- FDA Review Progress: On December 29, 2025, Inovio disclosed that the FDA accepted its INO-3107 application but did not receive accelerated review, leading to a 24.45% stock price drop to $1.73 per share, further exacerbating investor losses.
- Investor Rights Affected: Due to the company's failure to meet submission timelines and changes in review status, investors are facing significant financial losses, prompting the Law Offices of Howard G. Smith to urge affected investors to reach out for potential claims to recover losses.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Initiated: The Portnoy Law Firm has filed a class action against Inovio Pharmaceuticals on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 7, 2026, indicating the urgency of legal recourse.
- False Statements Allegations: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which misled investors regarding the prospects of the INO-3107 Biologics License Application, thereby undermining investor confidence.
- FDA Review Developments: On December 29, 2025, the FDA accepted Inovio's Biologics License Application for INO-3107 but noted that the company did not provide adequate information to justify eligibility for accelerated approval, highlighting significant regulatory compliance challenges for Inovio.
- Stock Price Volatility: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73, reflecting market pessimism regarding the company's prospects and investor concerns over potential losses.
See More
INOVIO to Participate in Multiple Scientific and Investor Conferences
- Conference Participation: INOVIO will present its DNA immunotherapy INO-3107 at the American Association for Cancer Research Immuno-Oncology Conference on February 18 in Los Angeles, showcasing its ability to activate and enrich CD4+ T cell responses in clinical patients, which is expected to enhance the company's visibility in cancer treatment.
- Virtual Conference Engagement: The company will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, sharing the latest advancements in DNA drug development, thereby attracting investor interest and bolstering market confidence.
- Biologics Festival Presentation: On March 4, INOVIO will present the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies at the Festival of Biologics in San Diego, demonstrating its research achievements in combating COVID-19, which could enhance the company's influence in the biopharmaceutical sector.
- Investor Meeting Schedule: During the Citizens Life Sciences Conference on March 10, INOVIO will conduct one-on-one meetings with investors, aiming to strengthen investor trust through direct engagement and facilitate future capital inflows.
See More
Inovio Pharmaceuticals Faces Class Action for Securities Fraud
- Lawsuit Background: DJS Law Group reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, covering the period from October 10, 2023, to December 26, 2025, with a deadline of April 7, 2026.
- False Statement Allegations: The complaint alleges that Inovio made false and misleading statements to the market, indicating that manufacturing deficiencies with its CELLECTRA device were likely to delay its BLA filing with the FDA.
- Evidence Collection Issues: The company failed to gather the necessary evidence to support a priority review by the FDA, meaning its public statements were false and materially misleading throughout the class period, potentially leading to investor losses.
- Investor Participation Opportunity: DJS Law Group encourages shareholders who purchased Inovio stock during the class period to contact them to participate in the lawsuit, noting that appointment as lead plaintiff is not required to partake in any recovery, emphasizing their commitment to investor rights.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Lawsuit Background: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Inovio Pharmaceuticals on behalf of investors who purchased securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, to apply as lead plaintiff.
- Allegation Details: The lawsuit claims that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which affected the likelihood of submitting the INO-3107 Biologics License Application (BLA) on time, thereby overstating its regulatory and commercial prospects.
- Stock Price Reaction: Following the FDA's acceptance of INO-3107's BLA application, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting market pessimism regarding the company's future.
- Next Steps: Investors who suffered losses during the class period or have questions about the allegations are encouraged to contact Bragar Eagel & Squire for more information and to explore their legal rights, indicating the firm's commitment to investor advocacy.
See More
